Stevanato Group (NYSE:STVN) Earns Equal Weight Rating from Morgan Stanley

Morgan Stanley reaffirmed their equal weight rating on shares of Stevanato Group (NYSE:STVN) in a research report sent to investors on Monday, Benzinga reports. They currently have a $30.00 price target on the stock.

STVN has been the topic of several other reports. Stephens restated an overweight rating and set a $38.00 target price on shares of Stevanato Group in a research report on Monday, March 25th. BNP Paribas initiated coverage on shares of Stevanato Group in a research note on Monday. They set an outperform rating on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Stevanato Group currently has an average rating of Moderate Buy and an average target price of €33.63 ($35.77).

Stevanato Group Trading Down 0.7 %

Shares of NYSE STVN opened at €26.54 ($28.23) on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. The business’s 50 day moving average is €30.39 and its two-hundred day moving average is €29.51. Stevanato Group has a 52-week low of €23.00 ($24.47) and a 52-week high of €36.30 ($38.62).

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of €0.19 ($0.20) by (€0.01) (($0.01)). The business had revenue of €320.60 million during the quarter, compared to analyst estimates of €326.85 million. Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.19 earnings per share. As a group, equities research analysts predict that Stevanato Group will post 0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

A number of large investors have recently added to or reduced their stakes in the company. Raymond James & Associates lifted its stake in shares of Stevanato Group by 0.9% in the third quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock worth $5,864,000 after acquiring an additional 1,806 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stevanato Group during the third quarter worth approximately $255,000. Calamos Wealth Management LLC acquired a new stake in Stevanato Group in the third quarter valued at $1,456,000. Conestoga Capital Advisors LLC grew its holdings in Stevanato Group by 19.7% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock worth $134,753,000 after acquiring an additional 746,136 shares in the last quarter. Finally, Fifth Third Bancorp raised its stake in shares of Stevanato Group by 70.1% in the 3rd quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock valued at $73,000 after purchasing an additional 1,019 shares in the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.